Article info
PDFReview
Cannabis and multiple sclerosis
- Correspondence to Dr Gillian Ingram, Neurology, Morriston Hospital, Swansea SA6 6NL, UK; drgillianingram{at}hotmail.com
Citation
Cannabis and multiple sclerosis
Publication history
- Received February 8, 2019
- Revised March 22, 2019
- Accepted March 26, 2019
- First published June 14, 2019.
Online issue publication
June 23, 2020
Article Versions
- Previous version (23 June 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Cannabis, cannabinoids, and cannabis-based medicines: future research directions for analgesia
- ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids
- Daring discourse – yes: practical considerations for cannabis use in the perioperative setting
- Effects of medical and non-medical cannabis use in older adults: protocol for a scoping review
- Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline
- Medical Marijuana and Opioids (MEMO) Study: protocol of a longitudinal cohort study to examine if medical cannabis reduces opioid use among adults with chronic pain
- Antinociception mechanisms of action of cannabinoid-based medicine: an overview for anesthesiologists and pain physicians
- The case for medical cannabis—an essay by M P Barnes
- State of the science: cannabis and cannabinoids in palliative medicine—the potential
- Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects